We are thrilled to announce the appointment of Phil Hudson as the newest member of the GINN team. Phil will spearhead membership and outreach initiatives across the UK and European markets, bringing a wealth of experience and insight to our mission of advancing tobacco harm reduction and fostering innovation in the novel nicotine industry. A…
The U.S. Food and Drug Administration (FDA) has taken a landmark step in tobacco harm reduction by authorizing the marketing of 20 ZYN nicotine pouch products. This authorization, granted under the Premarket Tobacco Product Application (PMTA) process, establishes a clear regulatory pathway for nicotine pouches, reinforcing their role as a viable alternative for adult smokers…
The growing popularity of nicotine pouches as a smoke-free alternative has positioned them as a pivotal tool in tobacco harm reduction. However, their rapid market growth has also drawn increased regulatory scrutiny, particularly in the European Union (EU). As policymakers deliberate over the future of these products, the question arises: Could nicotine pouches face stricter…
The rise of nicotine pouch use in Great Britain, while modest, signals a pivotal shift in tobacco consumption trends. According to a new study published in Nicotine and Tobacco Research by Dr. Leonie Brose, Laura Bunce, and Hazel Cheeseman, nicotine pouch usage has reached 5.4%. However, only 1% of respondents reported current use, suggesting that…
1. Executive Summary Safer nicotine products (SNPs), such as nicotine pouches, lozenges, gums, dissolvables and other reduced-risk nicotine alternatives, should not be regulated in the same manner as combustible smoking tobacco products and nicotine vaping products because they– • are smokeless and do not pose the same relative health risks; • readily contribute to a…
As the global conversation on tobacco harm reduction evolves, regulatory frameworks for novel nicotine products are under scrutiny. Broughton Life Sciences Ltd., a leading consultancy in life sciences, recently submitted comprehensive recommendations to the UK Parliament, offering a roadmap for establishing safety, quality, and compliance standards for nicotine pouches and other reduced-risk alternatives. Key Recommendations…
As nicotine products evolve, public health policies must adapt to reflect scientific evidence and advance harm reduction goals. Central to this evolution is the idea of risk-proportionate taxation—a fiscal framework that aligns tax rates with the relative health risks of different nicotine products. This approach not only supports harm reduction but also incentivizes smokers to…
As the U.K. Parliament advances the Tobacco and Vapes Bill, a key feature is the introduction of a licensing scheme for retailers of nicotine pouches and alternative nicotine products. This initiative aims to regulate sales and storage, ensuring public health and safety. What Retailers Need to Know 🔹 Dual Licensing Requirement: Retailers must obtain both…
As the UK Tobacco and Vapes Bill advances in the House of Commons, GINN is preparing to contribute its insights. We believe the regulatory framework must balance innovation with public health while ensuring consumer safety. Here’s what we propose: 🔹 Market Access: Introduce a clear and transparent notification process for manufacturers, requiring detailed disclosures of…
As the European Union considers new tax measures under the proposed revision of the Tobacco Excise Directive (TED), the focus on nicotine pouches highlights the growing debate over their regulation and taxation. This burgeoning segment within the nicotine market holds promise for harm reduction, but significant taxation could undermine its potential to encourage smokers to…